Welcome to the November 2020 edition of the Site Engagement newsletter. This newsletter is dedicated to keeping you informed of news and trends as it relates to site engagement within clinical development.
In this edition, read insights and updates from PRA’s Site Engagement Team. We explore the role of Clinical Trial Liaisons and how their work benefits clinical trial design and helps unite client teams that work with PRA. Also covered is an innovative SCD treatment method focused on genetic editing with CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) DNA and Cas (CRISPR-associated) enzymes.
Evidence Based and Site Focused Strategies to Enhance Clinical Trial Enrollment
Join PRA Health Sciences Vice President, Investigator Relations, Dr. Martin Lee, as he explores evidence based and site focused recruitment…
Symphony Health - A PRA Health Sciences Company. Where remarkable people turn healthcare data into actionable strategy.
Introduction to Patient Feasibility
Patient Feasibility is an area under-explored in the clinical trial industry. Currently, protocol and site feasibility are the primary methods of…